Product Description
ISM3412 is a novel and selective MAT2A inhibitor for the treatment of cancer. (Sourced from: https://insilico.com/events/aacr2023)
Mechanisms of Action: MAT2A Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: InSilico Medicine
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for ISM-3412](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ISM3412-101 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2028-03-31 |
21% |